Immune Modulation

Thymosin Alpha-1

Thymosin Alpha-1 (Tα1)

28-amino-acid immunomodulator · approved in 35+ countries (not US)

FDA Status
Not FDA-approved · Approved in Italy, China, others
Class
Thymic peptide · immunomodulator
Sequence
28 amino acids · acetylated N-terminus
Half-life
~2 hours

Mechanism of action

  • T-cell maturation and function enhancement
  • Toll-like receptor (TLR) modulation
  • Natural killer cell activity boost
  • Cytokine balance modulation

Research areas

  • Hepatitis B and C (approved indication abroad)
  • Sepsis and severe infections
  • Cancer immunotherapy adjunct
  • COVID-19 (used in China, Italy)

Evidence and clinical data

Strong international clinical evidence for hepatitis B/C. Phase II/III trials for sepsis. COVID-19 evidence emerged from Chinese and Italian centers in 2020-2022.

Safety profile

Excellent safety record over 30+ years of clinical use abroad. Common: injection-site reactions. Rare serious AEs.

Why this peptide is trending in 2026: Considered the "immune peptide of choice" in functional medicine circles. Long history of clinical use globally despite no FDA approval.
Educational use only. PeptideAdvance does not sell Thymosin Alpha-1, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.
Related Peptides

Other compounds in Immune Modulation